13 research outputs found
Epithelial-mesenchymal transition-associated microRNA/mRNA signature is linked to metastasis and prognosis in clear-cell renal cell carcinoma
Clear-cell renal cell carcinomas (ccRCCs) are genetically heterogeneous tumors
presenting diverse clinical courses. Epithelial-mesenchymal transition (EMT)
is a crucial process involved in initiation of metastatic cascade. The aim of
our study was to identify an integrated miRNA/mRNA signature associated with
metastasis and prognosis in ccRCC through targeted approach based on analysis
of miRNAs/mRNAs associated with EMT. A cohort of 230 ccRCC was included in our
study and further divided into discovery, training and validation cohorts. EMT
markers were evaluated in ccRCC tumor samples, which were grouped accordingly
to EMT status. By use of large-scale miRNA/mRNA expression profiling, we
identified miRNA/mRNA with significantly different expression in EMT-positive
tumors and selected 41 miRNAs/mRNAs for training phase of the study to
evaluate their diagnostic and prognostic potential. Fifteen miRNAs/mRNAs were
analyzed in the validation phase, where all evaluated miRNA/mRNA candidates
were confirmed to be significantly deregulated in tumor tissue. Some of them
significantly differed in metastatic tumors, correlated with clinical stage,
with Fuhrman grade and with overall survival. Further, we established an EMT-
based stage-independent prognostic scoring system enabling identification of
ccRCC patients at high-risk of cancer-related death. Finally, we confirmed
involvement of miR-429 in EMT regulation in RCC cells in vitro
Comparison of mobility shift affinity capillary electrophoresis and capillary electrophoresis frontal analysis for binding constant determination between human serum albumin and small drugs
In this study, two capillary electrophoresis–based ligand binding assays,
namely, mobility shift affinity capillary electrophoresis (ms-ACE) and capil-
lary electrophoresis-frontal analysis (CE-FA), were applied to determine binding
parameters of human serum albumin toward small drugs under similar exper-
imental conditions. The substances S-amlodipine (S-AML), lidocaine (LDC),
l-tryptophan (l-TRP), carbamazepine (CBZ), ibuprofen (IBU), and R-verapamil
(R-VPM) were used as the main binding partners. The scope of this comparative
study was to estimate and compare both the assays in terms of their primary mea-
sure’s precision and the reproducibility of the derived binding parameters. The
effective mobility could be measured with pooled CV values between 0.55% and
7.6%. The precision of the r values was found in the range between 1.5% and 10%.
Both assays were not universally applicable. The CE-FA assay could successfully
be applied to measure the drugs IBU, CBZ, and LDC, and the interaction toward
CBZ, S-AML, l-TRP, and R-VPM could be determined using ms-ACE. The aver-
age variabilities of the estimated binding constants were 64% and 67% for CE-FA
and ms-ACE, respectively
A de novo substitution in BCL11B leads to loss of interaction with transcriptional complexes and craniosynostosis
Craniosynostosis, the premature ossification of cranial sutures, is a developmental disorder of the skull vault, occurring in approximately 1 in 2250 births. The causes are heterogeneous, with a monogenic basis identified in ~25% of patients. Using whole-genome sequencing, we identified a novel, de novo variant in BCL11B, c.7C>A, encoding an R3S substitution (p.R3S), in a male patient with coronal suture synostosis. BCL11B is a transcription factor that interacts directly with the nucleosome remodelling and deacetylation complex (NuRD) and polycomb-related complex 2 (PRC2) through the invariant proteins RBBP4 and RBBP7. The p.R3S substitution occurs within a conserved amino-terminal motif (RRKQxxP) of BCL11B and reduces interaction with both transcriptional complexes. Equilibrium binding studies and molecular dynamics simulations show that the p.R3S substitution disrupts ionic coordination between BCL11B and the RBBP4-MTA1 complex, a subassembly of the NuRD complex, and increases the conformational flexibility of Arg-4, Lys-5 and Gln-6 of BCL11B. These alterations collectively reduce the affinity of BCL11B p.R3S for the RBBP4-MTA1 complex by nearly an order of magnitude. We generated a mouse model of the BCL11B p.R3S substitution using a CRISPR-Cas9-based approach, and we report herein that these mice exhibit craniosynostosis of the coronal suture, as well as other cranial sutures. This finding provides strong evidence that the BCL11B p.R3S substitution is causally associated with craniosynostosis and confirms an important role for BCL11B in the maintenance of cranial suture patency
The Dynamic Transcriptional Cell Atlas of Testis Development during Human Puberty
The human testis undergoes dramatic developmental and structural changes during puberty, including proliferation and maturation of somatic niche cells, and the onset of spermatogenesis. To characterize this understudied process, we profiled and analyzed single-cell transcriptomes of similar to 10,000 testicular cells from four boys spanning puberty and compared them to those of infants and adults. During puberty, undifferentiated spermatogonia sequentially expand and differentiate prior to the initiation of gametogenesis. Notably, we identify a common pre-pubertal progenitor for Leydig and myoid cells and delineate candidate factors controlling pubertal differentiation. Furthermore, pre-pubertal Sertoli cells exhibit two distinct transcriptional states differing in metabolic profiles before converging to an alternative single mature population during puberty. Roles for testosterone in Sertoli cell maturation, antimicrobial peptide secretion, and spermatogonial differentiation are further highlighted through single-cell analysis of testosterone-suppressed transfemale testes. Taken together, our transcriptional atlas of the developing human testis provides multiple insights into developmental changes and key factors accompanying male puberty
Structural and non-coding variants increase the diagnostic yield of clinical whole genome sequencing for rare diseases
BACKGROUND: Whole genome sequencing is increasingly being used for the diagnosis of patients with rare diseases. However, the diagnostic yields of many studies, particularly those conducted in a healthcare setting, are often disappointingly low, at 25-30%. This is in part because although entire genomes are sequenced, analysis is often confined to in silico gene panels or coding regions of the genome.METHODS: We undertook WGS on a cohort of 122 unrelated rare disease patients and their relatives (300 genomes) who had been pre-screened by gene panels or arrays. Patients were recruited from a broad spectrum of clinical specialties. We applied a bioinformatics pipeline that would allow comprehensive analysis of all variant types. We combined established bioinformatics tools for phenotypic and genomic analysis with our novel algorithms (SVRare, ALTSPLICE and GREEN-DB) to detect and annotate structural, splice site and non-coding variants.RESULTS: Our diagnostic yield was 43/122 cases (35%), although 47/122 cases (39%) were considered solved when considering novel candidate genes with supporting functional data into account. Structural, splice site and deep intronic variants contributed to 20/47 (43%) of our solved cases. Five genes that are novel, or were novel at the time of discovery, were identified, whilst a further three genes are putative novel disease genes with evidence of causality. We identified variants of uncertain significance in a further fourteen candidate genes. The phenotypic spectrum associated with RMND1 was expanded to include polymicrogyria. Two patients with secondary findings in FBN1 and KCNQ1 were confirmed to have previously unidentified Marfan and long QT syndromes, respectively, and were referred for further clinical interventions. Clinical diagnoses were changed in six patients and treatment adjustments made for eight individuals, which for five patients was considered life-saving.CONCLUSIONS: Genome sequencing is increasingly being considered as a first-line genetic test in routine clinical settings and can make a substantial contribution to rapidly identifying a causal aetiology for many patients, shortening their diagnostic odyssey. We have demonstrated that structural, splice site and intronic variants make a significant contribution to diagnostic yield and that comprehensive analysis of the entire genome is essential to maximise the value of clinical genome sequencing.</p
Urinary microRNAs as a new class of noninvasive biomarkers in oncology, nephrology, and cardiology.
International audienceMicroRNAs (miRNAs) are small noncoding RNAs that posttranscriptionally regulate gene expression. In the last decade, number of evidences showing miRNAs contribution to the regulation of apoptosis, cellular proliferation, differentiation, and other important cellular processes is constantly growing. Specific miRNA expression signatures have been identified in variety of human cancers as well as pathologies of cardiovascular and urinary systems. Our chapter focuses on the potential of urinary miRNAs to serve as biomarkers in uro-oncology, nephrology, and cardiology. We discuss in detail recent knowledge about the origin of urinary miRNAs, their stability, quality control, and their utility as a potential new class of biomarkers in medicine. Finally, we summarize the studies focusing on detection and characterization of urinary miRNAs as potential biomarkers in urologic cancers, nephrology, and cardiology